We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0025 | -0.14% | 1.76 | 1.73 | 1.76 | 1.75 | 1.73 | 1.74 | 7,822,292 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.97 | 19.87M |
TIDMHEMO
RNS Number : 2080P
Hemogenyx Pharmaceuticals PLC
07 February 2023
7 February 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Admission of Shares to Official List
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has applied to the Financial Conduct Authority to admit 2 ordinary shares of 1 pence each in the Company to the Official List in relation to a historical transaction. It is expected that the shares will be admitted on or around 8 February 2023. The total issued share capital of the Company will remain 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com Peter Redmond, Director peter.redmond@hemogenyx.com Tel: +44 (0)20 3470 SP Angel Corporate Finance LLP 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Tel: +44 (0)20 7469 Peterhouse Capital Limited 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSZZGGZDNFGFZM
(END) Dow Jones Newswires
February 07, 2023 09:30 ET (14:30 GMT)
1 Year Hemogenyx Pharmaceuticals Chart |
1 Month Hemogenyx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions